A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
Laufzeit: 01.01.2020 - 31.12.2024
imported
Kurzfassung
paediatric patients from 6 months to <18 years of age at enrolment, with relapsed or refractory non-CNS solid tumours for whom there are no standard treatment options.
